Cardiovascular morbidity in psoriasis: Epidemiology, pathomechanisms, and clinical consequences

Giornale Italiano di Dermatologia e Venereologia

Volumn 143, Issue 5, 2008, Pages 307-313

  Boehncke, W H ^a,b   Boehncke, S ^a  

^a GOETHE UNIVERSITY   (Germany)

^b Section of Endocrinology Diabetes and Metabolism Department of Internal Medicine Johann Wolfgang Goethe University ^*  (Germany)

Author keywords

Adipokines; Atherosclerosis; Drug interactions; Insulin resistance; Metabolic syndrome; Psoriasis, co morbidity; Resistin

Indexed keywords

ANTIPSORIASIS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EFALIZUMAB; FOLIC ACID; FUMARIC ACID ETHYL ESTER; HYDROXYCHLOROQUINE; INTERFERON; LEFLUNOMIDE; LITHIUM; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; RETINOID; TERBINAFINE; TETRACYCLINE;

CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMORBIDITY; DIABETES MELLITUS; DISEASE ASSOCIATION; HEART FAILURE; HEART INFARCTION; HOMOCYSTINURIA; HUMAN; HYPERTENSION; IMMUNOPATHOGENESIS; INSULIN RESISTANCE; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; OBESITY; PREVALENCE; PSORIASIS; RETROSPECTIVE STUDY; REVIEW; RISK REDUCTION; SMOKING; SYSTEMIC THERAPY;

EID: 55949117915     PISSN: 03920488     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Schön MP, Boehncke W-H. Psoriasis. New Engl J Med 2005;352:1899-912.
2. Sabat R, Philipp S, Höflich C, Kreutzer S, Wallace E, Asadullah K et al. Immunopathogenesis of psoriasis. Exp Dermatol 2007;16:779-98.
3. Asadullah K, Volk H-D, Sterry W. Novel immunotherapies for psoriasis. Trends Immunol 2002;23:47-53.
4. Boehncke W-H. Immunomodulatory drugs for psoriasis. Br Med J 2003;327:634-5
5. Maradit-Kremers H, Nicola PJ, Crowson CS, Ballman KV, Gabriel SE. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005;52:722-32.
6. Popa C, Netea MG, Radstake T, van der Meer JW, Stalenhoef AF, van Riel PL, et al. Influence of anti-tumor necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 2005;64:303-5.
7. Mattey DL, Glossop JR, Nixon NB, Dawes PT. Circulating levels of tumor necrosis factor receptors are highly predictive of mortality in patients with rheumatoid arthritis. Arthr Rheum 2007;56:3940-8.
8. Dixon WG, Watson KD, Lunt M, Hyrich KL. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to antitumor necrosis factor 〈 therapy. Arthr Rheum 2007;56:2905-12.
9. Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatol Treat 2008;19:5-21.
10. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64(Suppl. 2):ii14-7.
11. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995;32:982-6.
12. Mallbris L, Akre O, Granath F, Yin L, Lindelöf B, Ekbom A et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004;19:225-30.
13. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006;296:1735-41.
14. Ludwig RJ, Herzog C, Rostock A, Ochsendorf FR, Zollner TM, Thaci D et al. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007;156:271-6.
15. Seishima M, Seishima M, Mori S, Noma A. Serum lipid and apolipoprotein levels in patients with psoriasis. Br J Dermatol 1994;130:738-42.
16. Mallbris L, Granath F, Hamsten A, Stahle M. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol 2006;54:614-21.
17. Naldi L, Chatenoud L, Linder D, Belloni Fortina A, Peserico A et al. Sigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol 2005;125:61-7.
18. Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A et al. Prevalence of metabolic sindrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007;157:68-73.
19. Shapiro J, Cohen AD, David M, Hodak E, Chodik G, Viner A et al. The association between psoriasis, diabetes mellitus, and atherosclerosis in Israel: a case-control study. J Am Acad Dermatol 2007;56:629-34.
20. Hansson GI. Inflammation, atherosclerosis, and coronary artery disease. New Engl J Med 2005;352:1685-95.
21. Rocha-Pereira P, Santos-Silva A, Rebelo I, Figueiredo A, Quintanilha A, Traxeira F. The inflammatory response in mild and in severe psoriasis. Br J Dermatol 2004;150:917-28.
22. Chodorowska G, Wojnowska D, Juszkiewicz-Borowiec M. C-reactive protein and alpha2-macroglobulin plasma activity in medium-severe and severe psoriasis. J Eur Acad Dermatol Venerol 2004;18:180-3.
23. Ludwig RJ, Schultz JE, Boehncke W-H, Podda M, Tandi C, Krombach F et al. Activated, not resting, platelets increase leukocyte rolling in urine skin utilizing a distinct set of adhesion molecules. J Invest Dermatol 2004;122:830-6.
24. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005;115:1111-9.
25. Boehncke W-H, Schön MP. Interfering with leukocyte rolling - a promising therapeutic approach in inflammatory skin disorders? Trends Pharmacol Sci 2003;24:49-52.
26. Semenkovich CF. Insulin resistance and atherosclerosis. J Clin Invest 2006;116:1813-22.
27. Taniguchi CM, Emanuelli B, Kahn C. Critical nodes in signalling pathways: insights into insulin action. Nat Rev Mol Cell Biol 2006;7:85-96.
28. Kim J, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006;113:1888-904.
29. Zarubin T, Han J. Activation and signalling of the p38 MAP kinase pathway. Cell Res 2005;15:11-8.
30. Li G, Barrett EJ, Barrett MO, Cao W, Liu Z. TNF-α induces insulin resistance in endothelial cells via a p38 MAPK-dependent pathway. Endocrinology 2007;148:3356-63.
31. Schön MP, Zollner TM, Boehncke W-H. The molecular basis of lymphocyte recruitment to the skin: clues for pathogenesis and selective therapies of inflammatory disorders. J Invest Dermatol 2003;121:951-62.
32. Ludwig RJ, Schön MP, Boehncke W-H. P-selectin: a common therapeutic target for cardiovascular disorders, inflammation, and tumour metastasis. Exp Opin Ther Targets 2007;11:1103-17.
33. Schächinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 200;101:1899-906.
34. Fichtlscherer S, Rössig L, Breuer S, Vasa M, Dimmeler S, Zeiher AM. Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure. Circulation 2001;104:3023-5.
35. Hürlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O et al. Anti-tumor necrosis factor-α treatment improves endothelial function in patients with rheumatoid arthritis. Circulation 2002;106:2184-7.
36. Jacobsson LT, Turesson C, Gülfe A, Kapetanovic MC, Petersson IF, Saxne T et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005;32:1213-8.
37. Boehncke S, Thaci D, Beschmann H, Ludwig RJ, Ackermann H, Badenhoop K et al. Psoriasis patients show signs of insulin resistance. Br J Dermatol 2007;157:1249-51.
38. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM et al. The hormone resistin links obesity to diabetes. Nature 2001;409:307-12.
39. Senolt L, Housa D, Vernerova Z, Jirasek T, Svobodova R, Veigl D et al. Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum. Ann Rheum Dis 2007;66:458-63.
40. Nast A, Kopp I, Augustin M, Banditt KB, Boehncke W-H, Follmann M et al. German evidence-based guidelines for the treatment of psoriasis vulgaris. Arch Dermatol Res 2007;299;111-38.
41. Prodanovich S, Ma F, Taylor JR, Pezon C, Fasihi T, Kirsner RS. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol 2005;52: 262-7.
42. Mrowietz U, Elder JT, Barker J. The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Arch Dermatol Res 2006;298:309-19.